|
Category:pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | white crystalline powder (est) |
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 274.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 576.96 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 577.00 °F. TCC ( 302.70 °C. ) (est)
|
| logP (o/w): | -0.070 |
| Soluble in: |
| | water, 722 mg/L @ 25 °C (exp) | | | water, 1292 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-dog LD50 250 mg/kg
"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 124, 1973.
oral-man TDLo 12857 ug/kg/9D
GASTROINTESTINAL: NAUSEA OR VOMITING
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
American Journal of Medicine. Vol. 70, Pg. 1163, 1981.
oral-man TDLo 75 mg/kg/30W-I
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
BEHAVIORAL: MUSCLE WEAKNESS
GASTROINTESTINAL: OTHER CHANGES
Rinsho Shinkeigaku. Clinical Neurology. Vol. 17, Pg. 162, 1977.
intraperitoneal-mouse LD50 578 mg/kg
"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 77, 1965.
intravenous-mouse LD50 590 mg/kg
PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Journal of Pharmacology and Experimental Therapeutics. Vol. 134, Pg. 273, 1961.
oral-mouse LD50 1175 mg/kg
Farmatsevtichnii Zhurnal Vol. (1), Pg. 44, 1983.
unreported-mouse LD50 1100 mg/kg
Farmatsevtichnii Zhurnal Vol. (5), Pg. 26, 1983.
intravenous-rabbit LD50 461 mg/kg
"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 124, 1973.
intraperitoneal-rat LD50 234 mg/kg
"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 124, 1973.
intravenous-rat LD50 990 mg/kg
Journal of Pharmacology and Experimental Therapeutics. Vol. 140, Pg. 249, 1963.
oral-rat LD50 2750 mg/kg
Toxicology and Applied Pharmacology. Vol. 1, Pg. 333, 1959.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 1470 mg/kg
"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 124, 1973.
subcutaneous-rat LD50 1270 mg/kg
"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 124, 1973.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | pharmaceuticals / chemical synthisis |
| Recommendation for hydrochlorothiazide usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for hydrochlorothiazide flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
| | 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lamda6,2,4-benzothiadiazine-7-sulfonamide |
| NIST Chemistry WebBook: | Search Inchi |
| Canada Domestic Sub. List: | 58-93-5 |
| Pubchem (cid): | 3639 |
| Pubchem (sid): | 134972118 |
Other Information:
| (IUPAC): | Atomic Weights of the Elements 2011 (pdf) |
| Videos: | The Periodic Table of Videos |
| tgsc: | Atomic Weights use for this web site |
| (IUPAC): | Periodic Table of the Elements |
| CHEBI: | View |
| CHEMBL: | View |
| KEGG (GenomeNet): | C07041 |
| HMDB (The Human Metabolome Database): | HMDB01928 |
| FooDB: | FDB022745 |
| MedlinePlusSupp: | View |
| ChemSpider: | View |
| Wikipedia: | View |
Formulations/Preparations:
•capsules: 12.5 mg: hydrochlorothiazide capsules, mylan; microzide, watson. oral solution: 50 mg5 ml: hydrochlorothiazide solution, roxane. tablets: 25 mg: aquazide-25, western research; hydrodiuril (scored), merck; oretic, abbott; 50 mg: aquazide-h, western research; ezide, economed; hydrodiuril (scored), merck; 100 mg: hydrochlorothiazide tablets, ivax.
•oral tablets, film-coated, 250 mg methylodopa and hydrochlorothiazide 15 mg: aldoril (with propylene glycol), merck; methyldopa and hydrochlorothiazide tablets, endo, major, mylan. 250 mg methyldopa and hydrochlorothiazide 25 mg, aldoril (with propylene glycol), merck; methyldopa and hydrochlorothiazide tablets, endo, major, mylan; 500 mg methyldopa and hydrochlorothiazide 30 mg, aldoril d (with propylene glycol), merck. methyldopa and hydrochlorothiazide
•oral capsules, extended-release: 80 mg propranolol hydrochloride and hydrochlorothiazide 50 mg: inderide la, wyeth-ayerst; 120 mg propranolol hyrochloride hydrochlorothiazide 50 mg: inderide la, wyeth-ayerst; 160 mg propranolol hydrochloride and hydrochlorothiazide 50 mg: inderide la, wyeth-ayerst. tablets: 40 mg propranolol hydrochloride and hydrochlorothiazide 25 mg, inderide (scored), wyeth-ayerst; propranolol hydrochloride and hydrochlorothiazide tablets, barr, mylan, purepac, sidmak; 80 mg propranolol hydrochloride and hydrochlorothazide 25 mg: inderide (scored), wyeth-ayerst; propranolol hydrochloride and hydrochlorothiazide tablets, barr, mylan, purepac, sidmak. propranolol hydrochloride and hydrochlorothiazide
•oral capsules: 37.5 mg triamterene and hydrochlorothiazide 25 mg: dyazide (with benzyl alcohol and povidone), glaxosmithkline; 50 mg triamterene and hydrochlorothiazide 25 mg: triameterene and hydrochlorothiazide capsules, geneva, ivax, major, martex; oral tablets: 37.5 mg triamterene and hydrochlorothiazide 25 mg: maxzide (scored), bertek; 75 mg triamterene and hydrochlorothiazide 50 mg, maxzide (scored), bertek. triamterene and hydrochlorothiazide (co-triamterzide)
•oral capsules: 25 mg with hydralazine hydrochloride 25 mg: hydralazine hydrochloride with hydrochlorothiazide capsules, major, united research; hydra-zide, par; 50 mg with hydralazine hydrochloride 50 mg: hydra-zide, par; 50 mg with hydralazine hydrochloride 100 mg: hydra-zide, par. tablets: 6.25 mg with benazepril 5 mg: lotensin hct (scored), novartis; 12.5 mg with benazepril 10 mg: lotensin hct (scored), novartis; 12.5 mg with benazepril 20 mg: lotensin hct (scored), novartis; 12.5 mg with irbesartan 150 mg, avalide, bristol-myers squibb (also promoted by sanofi-synthelabo); 12.5 mg with irbesartan 300 mg, avalide, briston-meyers squibb (also promoted by sanofi-synthelabo); 12.5 mg with lisinopril 10 mg: prinzide, merck; zestoretic, astrazeneca; 12.5 mg with lisinopril 20 mg: prinzide, merck; zestoretic, astrazeneca; 12.5 mg with valsartan 80 mg: diovan hct, novartis; 12.5 mg with valsartan 160 mg: diovan hct, novartis; 15 mg with hydralazine hydrochloride 25 mg and reserpine 0.1 mg; 25 mg with benazepril 20 mg: lotensin hct (scored), novartis; 25 mg with lisinopril 20 mg: prinzide, merck; zestoretic, astrazeneca. tablets, film-coated: 6.25 mg with bisoprolol fumarate 2.5 mg: ziac, lederle; 6.25 mg with bisoprolol fumarate 5 mg: ziac, lederle; 6.25 mg with bisoprolol fumarate 10 mg: ziac, lederle; 12.5 mg with losartan potassium 50 mg: hyzaar, merck; 12.5 mg with moexipril hydrochloride 7.5 mg: uniretic (scored), schwarz; 12.5 mg with quinapril hydrochloride 10 mg (of quinapril): accuretic (with povidone; scored), parke-davis; 12.5 mg with quinapril hydrochloride 20 mg (of quinapril): accuretic (with povidone; scored), parke-davis; 25 mg with losartan potassium 100 mg: hyzaar, merck; 25 mg with moexipril hydrochloride 15 mg: uniretic (scored), schwarz; 25 mg with quinapril hydrochloride 20 mg (of quinapril): accuretic (with povidone; scored), parke-davis. hydrochlorothiazide combinations
•oral tablets: 25 mg captopril and hydrochlorothiazide 15 mg: capozide (scored), bristol-myers squibb; 25 mg captopril and hydrochlorothiazide 25 mg: capozide (scored), bristol-mayers squibb; captopril and hydrochlorothiazide tablets, endo, geneva, ivax, mylan, teva; 50 mg captopril and hydrochlorothiazide 15 mg: capozide (scored), bristol-meyers squibb; captopril and hydrochlorothiazide tablets, endo, geneva, ivax, mylan, teva; 50 mg captopril and hydrochlorothiazide 25 mg: capozide (scored), briston-meyers squibb; captopril and hydrochlorothiazide tablets, endo, geneva, ivax, mylan, teva. captopril and hydrochlorothiazide
•oral tablets: 50 mg metoprolol tartrate and hydrochlorothiazide 25 mg: lopressor hct (with povidone; scored), novartis; 100 mg metoprolol tartrate and hydrochlorothiazide 25 mg: lopressor hct (with povidone; scored), novartis; 100 mg metoprolol tartrate and hydrochlorothiazide 50 mg: loperssor hct (with povidone; scored), novartis. metoprolol tartrate and hydrochlorothiazide
•tablets, 25, 50, and 100 mg. oral solution, 50 mg5 ml. concentrated oral solution, 100 mgml.
•oral tablets: 5 mg of anhydrous amiloride hydrochloride and hydrochlorothiazide 50 mg, moduretic (scored), merck. amiloride hydrochloride and hydrochlorothiazide
•oral tablets: 10 mg timolol maleate and hydrochlorothiazide 25 mg: timolide (with povidone; scored), merck. timolol maleate and hydrochlorothiazide
•oral tablets: 25 mg spironolacton adn hydrochlorothiazide 25 mg. tablets, film-coated: 25 mg spironolactone and hydrochlorothiazide 25 mg: aldactazide (with povidone), pharmacia; spironolactone and hydrochlorothiazide tablers, major, mutual, mylan, udl, url; 50 mg spironolactone and hydrochlorothiazide 50 mg: aldactazide (with povidone; scored), pharmacia. spironolactone and hydrochlorothiazide
•oral tablets: 5 mg enalapril maleate and hydrochlorothiazide 12.5 mg: vaseretic, merck; 10 mg enalapril maleate and hydrochlorothiazide 25 mg: vaseretic, merck. enalapril maleate and hydrochlorothiazide
|
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | accuretic | | | acuilix | | | acuretic | | | aldactazide | | | aldazida | | | aldectazide 50/50 | | | aldoril | | | apo-hydro | | | apresazide | | | apresoline-esidrix | | | aquarills | | | aquarius | | | aquazide H | | | aquazide-H | | | avalide | | 2H-1,2,4- | benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-, 1, 1-dioxide | | | bremil | | | briazide | | | CAM-AP-ES | | | caplaril | | | carozide | | | catiazida | | 6- | chlor-3,4-dihydro-2H-1,2,4-benzothiadiazin-7-sulfonamid-1,1-dioxid | | | chlorizide | | 6- | chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lamda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide | | 6- | chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lamda6-benzo[1,2,4]thiadiazine-7-sulfonic acid amide | | 6- | chloro-1,1-dioxo-2H,3H,4H-benzo[e]1,2,4-thiadiazine-7-sulfonamide | | 6- | chloro-1,1-dioxo-3,4-dihydro-2H-1lamda6,2,4-benzothiadiazine-7-sulfonamide | | 6- | chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide | | 6- | chloro-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide | | 6- | chloro-3,4-dihydro-7-sulfamoyl-2H-1,2, 4-benzothiadiazine 1,1-dioxide | | 6- | chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide | | 6- | chloro-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide | | 6- | chloro-7-sulfamoyl-3, 4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide | | 6- | chloro-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide | | 6- | chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide | | 6- | chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide | | | chlorosulphadil | | | chlorosulthiadil | | | chlorsulfonamidodihydrobenzothiadiazine dioxide | | | chlorzide | | | chlothia | | | cidrex | | | clorana | | neo | codema | | neo- | codema | | | concor plus | | | condiuren | | | diaqua | | | dichlorosal | | | dichlothiazide | | | dichlotiazid | | | dichlotride | | | diclot ride | | | diclotride | | | didral | | | dihydran | | 3,4- | dihydro-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide | | 3,4- | dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothiadiazine-1,1-dioxide | | 3,4- | dihydro-6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide | | | dihydrochlorothiazid | | 3,4- | dihydrochlorothiazide | | | dihydrochlorurite | | | dihydroxychlorothiazidum | | | direma | | | disalunil | | | disothiazid | | | diu-melusin | | | diurogen | | | dixidrasi | | | drenol | | | dyazide | | | esidrex | | | esidrix | | | esimil | | | esoidrina | | neo | flumen | | neo- | flumen | | | fluvin | | | hidril | | | hidro-niagrin | | | hidrochlortiazid | | | hidroronol | | | hidrosaluretil | | | hidrotiazida | | | hyclosid | | | hydra-zide | | | hydrap-ES | | | hydril | | | hydro par | | | hydro-aquil | | | hydro-chlor | | | hydro-D | | | hydro-reserp | | | hydro-ride | | | hydro-saluric | | | hydro-T | | | hydrochloro thiazide | | | hydrochlorothiazid | | | hydrochlorthiazide | | | hydrochlorthiazidum | | | hydrocot | | | hydrodiuretic | | | hydrodiuril | | | hydrosaluric | | | hydrothide | | | hydrozide | | | hypothaizide | | | hypothiazid | | | hytrid | | | hyzaar | | | idrotiazide | | | inderide | | | indroclor | | | ivaugan | | | jen-diril | | | lopressor HCT | | | lotensin HCT | | | manuril | | | maschitt | | | maxzide | | | mazide 25 mg | | | medozide | | | megadiuril | | | microzide | | | mictrin | | | mikorten | | neo- | minzil | | | modurcen | | | moduretic | | | monopril-HCT | | | natrinax | | | nefrix | | | nefrol | | | newtolide | | | normozide | | | novodiurex | | | oretic | | | pantemon | | | panurin | | | prinzide | | | quinaretic | | | raunova plus | | | ro-hydrazide | | | saldiuril | | | sectrazide | | | selozide | | | ser-a-gen | | | ser-ap-es | | | servithiazid | | | spironazide | | | tandiur | | | thiaretic | | | thiuretic | | | thlaretic | | | timolide | | | unazid | | | unipres | | | uniretic | | | urodiazin | | | urozide | | | vaseretic | | | vasoretic | | | vetid rex | | | vetidrex | | | viskazide | | | zestoretic | | | ziac | | | zide |
Articles:
| PubMed:Diuretic Exposure in Premature Infants from 1997 to 2011. |
| PubMed:Multi-residue analytical methodology-based liquid chromatography-time-of-flight-mass spectrometry for the analysis of pharmaceutical residues in surface water and effluents from sewage treatment plants and hospitals. |
| PubMed:Study on diuretic activity of saffron (stigma of Crocus sativus L.) Aqueous extract in rat. |
| PubMed:Application of the Dynamic Gastric Model to evaluate the effect of food on the drug release characteristics of a hydrophilic matrix formulation. |
| PubMed:Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. |
| PubMed:What can we do to make antihypertensive medications taste better for children? |
| PubMed:Azilsartan/chlorthalidone combination therapy for blood pressure control. |
| PubMed:Determination of diuretics and laxatives as adulterants in herbal formulations for weight loss. |
| PubMed:Pharmaco-nutrient interactions - a systematic review of zinc and antihypertensive therapy. |
| PubMed:Azilsartan, aliskiren, and combination antihypertensives utilizing Renin-Angiotensin-aldosterone system antagonists. |
| PubMed:[Study on the proficiency testing program of pharmaceutical preparation analysis]. |
| PubMed:When one drug affects 2 patients: a review of medication for the management of nonlabor-related pain, sedation, infection, and hypertension in the hospitalized pregnant patient. |
| PubMed:How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders? |
| PubMed:Palatability of crushed ß-blockers, converting enzyme inhibitors and thiazides. |
| PubMed:Aliskiren: An orally active renin inhibitor. |
| PubMed:Herb-drug interaction between the extract of Hibiscus sabdariffa L. and hydrochlorothiazide in experimental animals. |
| PubMed:Suitability of a flat die press for the manufacture of pharmaceutical pellets by extrusion/spheronization. |
| PubMed:[Simultaneous determination of five illegal drugs in weight control foods with solid phase extraction-high performance liquid chromatography]. |
| PubMed:Annual drug update: 2010 in review. |
| PubMed:LC-MS determination and pharmacokinetics of p-coumaric acid in rat plasma after oral administration of p-coumaric acid and freeze-dried red wine. |
| PubMed:The potential benefits of a garlic and hydrochlorothiazide combination as antihypertensive and cardioprotective in rats. |
| PubMed:Phenylalanine ammonia-lyase, polyphenol oxidase, and phenol concentration in fruits of Olea europaea L. cv. Picual, Verdial, Arbequina, and Frantoio during ripening. |
| PubMed:The potential for interaction of hydrochlorothiazide with garlic in rats. |
| PubMed:Investigation of some factors contributing to negative food effects. |
| PubMed:Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma. |
| PubMed:Aliskiren. |
| PubMed:An online field-amplification sample stacking method for the determination of diuretics in urine by capillary electrophoresis-amperometric detection. |
| PubMed:[Interaction of calcium drug and vitamin D3 with some medicines used in coronary heart disease therapy]. |
| PubMed:Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. |
| PubMed:Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. |
| PubMed:Hyponatremia as a complication of selective serotonin reuptake inhibitors. |
| PubMed:Nebivolol: new therapy update. |
| PubMed:Clinical pharmacokinetics of losartan. |
| PubMed:The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. |
| PubMed:Bone loss in rats with aldosteronism. |
| PubMed:Pharmacology of irbesartan. |
| PubMed:Bladder epithelial cell proliferation of rats induced by terephthalic acid-calculi. |
| PubMed:Sodium appetite induced in rats by chronic administration of a thiazide diuretic. |
| PubMed:Trandolapril: a newer angiotensin-converting enzyme inhibitor. |
| PubMed:Drug interactions with irbesartan. |
| PubMed:Isolation of a 2:1 hydrochlorothiazide-formaldehyde adduct impurity in hydrochlorothiazide drug substance by preparative chromatography and characterization by electrospray ionization LC-MS. |
| PubMed:['Licorice hypertension' also caused by licorice tea]. |
| PubMed:Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. |
| PubMed:Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. |
| PubMed:Identification of chlorothiazide and hydrochlorothiazide UV-A photolytic decomposition products. |
| PubMed:Effects of enalapril and hydrochlorothiazide on the salt-induced cardiac and renal hypertrophy in normotensive rats. |
| PubMed:A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. |
| PubMed:Captopril and hydrochlorothiazide (Capozide) combine to enhance the reduction in voluntary alcohol intake in rats. |
| PubMed:The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. |
| PubMed:Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. |
| PubMed:[Effect of XKJ-001, a crude drug preparation, on body water distribution and water excretion in mice]. |
| PubMed:Blood pressure hyperreactivity in non-human primates during dietary sodium combined with behavioral stress. |
| PubMed:Risk factor changes after cessation of intervention in the Multiple Risk Factor Intervention Trial. The MRFIT Research Group. |
| PubMed:Clinical pharmacology of cilazapril. |
| PubMed:Clinical pharmacology of cilazapril. |
| PubMed:Lisinopril: a new angiotensin-converting enzyme inhibitor. |
| PubMed:Determination of reserpine and hydrochlorothiazide in commercial tablets by liquid chromatography with fluorescence and UV absorption detectors in series. |
| PubMed:Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. |
| PubMed:Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products. |
| PubMed:The influence of dietary potassium on the renal tubular effect of hydrochlorothiazide in the rat. |
| PubMed:The clinical pharmacology of lisinopril. |
| PubMed:Acute effects of various diuretics on lithium clearance. Studies in rats on medium and low sodium diet. |
| PubMed:Susceptibilities of drugs to nitrosation under simulated gastric conditions. |
| PubMed:Kinetics of hydrochlorothiazide absorption in humans. |
| PubMed:[Decreased renal excretory capacity of uric acid in rats fed a low sodium diet under consecutive administration of thiazide diuretics]. |
| PubMed:Enalapril: a review of human pharmacology. |
| PubMed:Drug use in the United States in 1981. |
| PubMed:Efficacy and tolerance of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol, taken before or after food, in the treatment of hypertension. |
| PubMed:Role of dietary potassium and magnesium in diuretic-treated patients with cardiac insufficiency. |
| PubMed:Sodium balance and antidiuresis in thiazide-treated rats with diabetes insipidus. |
| PubMed:Multi-centre clinical investigation of indapamide in the United States: a review. |
| PubMed:The antidiuretic effect of chronic hydrochlorothiazide treatment in rats with diabetes insipidus: water and electrolyte balance. |
| PubMed:Managing diuretic-induced hypokalemia in ambulatory hypertensive patients. |
| PubMed:Influence of the dietary potassium intake on the natriuretic effect of hydrochlorothiazide in rats. |
| PubMed:Influence of food on the bioavailability of drugs. |
| PubMed:Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. |
| PubMed:Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. |
| PubMed:Metabolic balances of 210 Pb and 210Po at natural levels. |
| PubMed:Effect of hydrochlorothiazide on preference threshold of rats for NaCl solutions. |
| PubMed:[Electrolyte metabolism in hypertension]. |
| PubMed:TREATMENT OF HYPERTENSION WITH MEBUTAMATE ALONE AND IN COMBINATION WITH HYDROCHLOROTHIAZIDE. |
|
a thiazide diuretic often considered the prototypical member of this class. it reduces the reabsorption of electrolytes from the renal tubules. this results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. it has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. -- Pubchem
Hydrochlorothiazide (Apo-Hydro, Aquazide H, Microzide, Oretic), sometimes abbreviated HCT, HCTZ, or HZT is a popular diuretic drug that acts by inhibiting the kidney's ability to retain water. This reduces the volume of the blood, decreasing peripheral vascular resistance. Chlorothiazide, a carbonic anhydrase inhibitor. --Wikipedia [HMDB]
|
3D/inchi